Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-10, Stock:ABBV, The news for the past five days is as follows:
2018-11-30: NEWS1: U.S. Stocks Sprint Ahead to End a Blockbuster Week.NEWS2: Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar.NEWS3: 3 Beaten-Down Biotech Stocks to Buy Before the End of 2018.NEWS4: AbbVie Rises 3%.NEWS5: The New Amazon Blockchain Products Could Be Huge for AMZN.NEWS6: The New Amazon Blockchain Products Could Be Huge for AMZN.NEWS7: U.S.-China Trade Talks In Focus, While Just One Stock Sector Stands Out.NEWS8: Key Pharma Players With HIV Focus Ahead of World Aids Day.NEWS9: Key Pharma Players With HIV Focus Ahead of World Aids Day.NEWS10: The New Amazon Blockchain Products Could Be Huge for AMZN.NEWS11: AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer.NEWS12: Key Pharma Players With HIV Focus Ahead of World Aids Day.NEWS13: Pfizer Reaches Global Agreement With AbbVie; To Withdraw Pending Litigation.NEWS14: Pfizer Reaches Global Agreement With AbbVie; To Withdraw Pending Litigation.
2018-12-03: NEWS1: AbbVie Stock Could Become a New Happy Pill for Investors.NEWS2: IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).NEWS3: XLV, PFE, MRK, ABBV: ETF Inflow Alert.NEWS4: XLV, PFE, MRK, ABBV: ETF Inflow Alert.NEWS5: AbbVie Settles With Pfizer for Humira Biosimilar in U.S..NEWS6: AbbVie Settles With Pfizer for Humira Biosimilar in U.S..NEWS7: AbbVie's Imbruvica Achieves Up to 7-Year Progression-Free Survival in Leukemia Patients.NEWS8: AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018.NEWS9: AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018.NEWS10: AbbVie Settles With Pfizer for Humira Biosimilar in U.S..NEWS11: AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018.NEWS12: Today's Research Reports on Trending Tickers: AbbVie and OPKO Health.
2018-12-04: NEWS1: AbbVie Falls 3%.NEWS2: Roche Announces Positive Data on Venclexta/Venclyxto at ASH.NEWS3: Roche Announces Positive Data on Venclexta/Venclyxto at ASH.NEWS4: Roche Announces Positive Data on Venclexta/Venclyxto at ASH.NEWS5: IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018.NEWS6: JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial.NEWS7: JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial.NEWS8: AbbVie Stock Could Become a New Happy Pill for Investors.NEWS9: AbbVie Stock Could Become a New Happy Pill for Investors.
2018-12-06: NEWS1: AbbVie Stock Has a $10 Upside Opportunity — Buy It Now.NEWS2: AbbVie Stock Has a $10 Upside Opportunity — Buy It Now.NEWS3: AbbVie Falls 3%.NEWS4: AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study.NEWS5: AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study.NEWS6: AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study.NEWS7: AbbVie Stock Has a $10 Upside Opportunity — Buy It Now.NEWS8: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering.
2018-12-07: NEWS1: A Look at AbbVie’s Earnings Projections for 2018.NEWS2: Assessing AbbVie’s 2018 Revenue Projections.NEWS3: Analysts’ Recommendations for AbbVie in December.NEWS4: AbbVie Falls 4%.NEWS5: [$$] Congress to Drug Makers: Why Stock Buybacks Over Lowered Drug Prices?.

Answer: Rise